chronic myeloproliferative disorder: A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008)
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
445 |
4. Check minimum number of eventsNone |
445 |
5. Include endpointsNone |
445 |
6. Filter based on genotype QC (FinnGen only) |
445 |
Control definitions (FinnGen only)
- Control exclude
- MYELOPROF
Extra metadata
- First used in FinnGen datafreeze
- DF2, additional
Chronic myeloproliferative disease
based on the number of shared cases.
Similar with more cases:
Similar with less cases:
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2801 | 1352 | 1414 |
| Only index persons | 2074 | 1031 | 1043 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.04 | 0.04 | 0.04 |
| Only index persons | 0.04 | 0.04 | 0.04 |
| Median age at first event (years) | |||
| Whole population | 70.78 | 71.37 | 70.24 |
| Only index persons | 69.56 | 69.80 | 69.34 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 445 | 202 | 243 |
| Unadjusted period prevalence (%) | 0.09 | 0.07 | 0.11 |
| Median age at first event (years) | 67.54 | 66.15 | 68.69 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 396
- Matched controls
- 3961
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D47.1
ICD-10 Finland
Chronic myeloproliferative disease
+∞
323.0
396
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
186.9
304.8
298
63
L01XX05
ATC
hydroxycarbamide; oral
1318.4
227.0
200
*
9961/3-C42.1
ICD-O-3
Primary myelofibrosis of bone marrow
+∞
174.2
154
*
D45
ICD-10 Finland
Polycythaemia vera
+∞
155.8
139
*
D47.3
ICD-10 Finland
Essential (haemorrhagic) thrombocythaemia
+∞
134.2
121
*
XW000
NOMESCO Finland
Bone marrow biopsy
30.5
110.6
152
79
174
Kela drug reimbursment
Ruxolitinib
+∞
99.2
91
*
D75.2
ICD-10 Finland
Essential thrombocytosis
315.3
98.5
96
*
374
Kela drug reimbursment
Ruxolitinib
+∞
84.4
78
*
L01XE18
ATC
[U] ruxolitinib; oral
+∞
72.1
67
*
9950/3-C42.1
ICD-O-3
Polycythemia vera of bone marrow
+∞
68.8
64
*
L01EJ01
ATC
ruxolitinib; oral
+∞
65.4
61
*
M04AA01
ATC
allopurinol; systemic
7.6
61.5
173
367
9962/3-C42.1
ICD-O-3
Essential thrombocythemia of bone marrow
+∞
55.5
52
*
WW500
NOMESCO Finland
Blood transfusion
16.1
54.7
92
73
L03AB05
ATC
interferon alfa-2b; parenteral
207.6
53.4
54
*
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
63.9
52.3
60
11
L01XX35
ATC
anagrelide; oral
+∞
50.1
47
*
B03XA02
ATC
darbepoetin alfa; parenteral
23.8
49.2
71
36
TPH00
NOMESCO Finland
Phlebotomy
129.6
43.8
46
*
9960/3-C42.1
ICD-O-3
Myeloproliferative neoplasm, NOS, of bone marrow
+∞
42.5
40
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
6.1
41.6
131
297
SPAT1074
SPAT
Venesection
+∞
31.7
30
*
D75.9
ICD-10 Finland
Disease of blood and blood-forming organs, unspecified
51.2
27.9
33
7
D64.9
ICD-10 Finland
Anaemia, unspecified
4.2
22.6
95
274
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
4.8
22.3
81
202
Z94.8
ICD-10 Finland
Other transplanted organ and tissue status
53.1
21.4
25
5
B99
ICPC
Blood/lymph/spleen disease other
44.3
20.7
25
6
B03XA01
ATC
erythropoietin; parenteral
25.0
20.2
28
12
NEA10
NOMESCO Finland
Exploration of soft tissue of pelvis, percutaneous
210.0
19.7
20
*
L03AB04
ATC
interferon alfa-2a; parenteral
210.0
19.7
20
*
D47.9
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue, unspecified
198.9
18.7
19
*
212
Kela drug reimbursment
Gout
10.8
17.3
33
33
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.6
17.0
85
281
306
Kela drug reimbursment
Erythropoietin and darbepoetin
36.8
16.8
21
6
D72.8
ICD-10 Finland
Other specified disorders of white blood cells
29.0
16.7
22
8
L03AA04
ATC
NA
+∞
14.7
14
*
R50.9
ICD-10 Finland
Fever, unspecified
3.1
14.6
90
344
C92.0
ICD-10 Finland
Acute myeloblastic leukaemia [AML]
22.1
13.5
19
9
D46.7
ICD-10 Finland
Other myelodysplastic syndromes
29.5
13.1
17
6
R04.0
ICD-10 Finland
Epistaxis
3.6
12.7
59
182
XW4XT
NOMESCO Finland
Biopsy of other inner organ with radiological guidance guidance
134.0
12.5
13
*
XX7BT
NOMESCO Finland
Radioactive phosphorus therapy
134.0
12.5
13
*
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.2
11.8
149
839
D47.2
ICD-10 Finland
Monoclonal gammopathy of undetermined significance (MGUS)
13.1
11.8
20
16
T86.0
ICD-10 Finland
Bone-marrow transplant rejection
+∞
11.5
11
*
R16.1
ICD-10 Finland
Splenomegaly, not elsewhere classified
+∞
11.5
11
*
B01AC14
ATC
[U] anagrelide; oral
+∞
11.5
11
*
127
Kela drug reimbursment
Transplant complication
8.7
11.5
24
29
C03CA01
ATC
furosemide; systemic
2.1
11.3
170
1027
Z51.5
ICD-10 Finland
Palliative care
3.8
11.3
48
137
M10.9
ICD-10 Finland
Gout, unspecified
3.5
11.0
52
163
D46.9
ICD-10 Finland
Myelodysplastic syndrome, unspecified
16.6
10.4
16
10
D50.0
ICD-10 Finland
Iron deficiency anaemia secondary to blood loss (chronic)
5.6
9.9
28
53
9861/3-C42.1
ICD-O-3
Acute myeloid leukemia, NOS, of bone marrow
26.8
9.9
13
5
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.1
9.5
124
694
H02AB06
ATC
prednisolone; systemic
1.9
9.4
205
1407
A05AA02
ATC
ursodeoxycholic acid; oral
9.0
9.4
19
22
I81
ICD-10 Finland
Portal vein thrombosis
37.6
9.1
11
*
D73.5
ICD-10 Finland
Infarction of spleen
37.6
9.1
11
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.9
9.0
203
1401
I85.9
ICD-10 Finland
Oesophageal varices without bleeding
11.9
8.6
15
13
D73.1
ICD-10 Finland
Hypersplenism
+∞
8.4
8
*
C94.5
ICD-10 Finland
Acute myelofibrosis
+∞
8.4
8
*
2384A
ICD-9 Finland
Neoplasm of uncertain behaviour of other and unspecified sites and tissues, Polycythaemia vera
+∞
8.4
8
*
D47.0
ICD-10 Finland
Histiocytic and mast cell tumours of uncertain and unknown behaviour
+∞
8.4
8
*
C92.1
ICD-10 Finland
Chronic myeloid leukaemia [CML], BCR/ABL-positive
+∞
8.4
8
*
L04AD01
ATC
ciclosporin; systemic
6.7
8.3
20
31
C90.0
ICD-10 Finland
Multiple myeloma
7.8
8.2
18
24
J05AB11
ATC
valaciclovir; oral
2.5
8.2
66
290
B01AB05
ATC
enoxaparin; parenteral
1.9
7.9
148
942
B04
ICPC
Blood symptom/complaint
45.9
7.7
9
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
2.7
7.7
54
219
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
2.0
7.6
112
651
D75.1
ICD-10 Finland
Secondary polycythaemia
25.6
7.6
10
*
D47.7
ICD-10 Finland
Other specified neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue
81.5
7.4
8
*
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
5.0
7.3
22
46
I50.9
ICD-10 Finland
Heart failure, unspecified
2.2
7.2
78
396
D69.6
ICD-10 Finland
Thrombocytopenia, unspecified
5.8
7.2
19
34
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
3.4
7.0
33
104
T81.0
ICD-10 Finland
Haemorrhage and haematoma complicating a procedure, not elsewhere classified
3.0
7.0
40
144
B82
ICPC
Anaemia other/unspecified
4.5
7.0
23
53
J01MA12
ATC
levofloxacin; systemic
2.0
6.9
95
534
N02AA05
ATC
oxycodone; systemic
2.2
6.9
76
391
B74
ICPC
Malignant neoplasm blood other
22.9
6.7
9
*
R79.9
ICD-10 Finland
Abnormal finding of blood chemistry, unspecified
12.5
6.6
11
9
TGC00
NOMESCO Finland
Bronchial lavation
4.7
6.6
21
47
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
4.8
6.5
20
43
D75.0
ICD-10 Finland
Familial erythrocytosis
70.9
6.4
7
*
A02BC02
ATC
pantoprazole; systemic
1.7
6.3
260
2076
D50.9
ICD-10 Finland
Iron deficiency anaemia, unspecified
2.8
6.3
38
143
V03AC03
ATC
deferasirox; oral
+∞
6.3
6
*
2387X
ICD-9 Finland
Neoplasm of uncertain behaviour of other and unspecified sites and tissues, Other lymphatic and haematopoietic tissues[STATUS LYMPHO- ET MYELOPROLIFERATIVUS NUD]
+∞
6.3
6
*
WW306
NOMESCO Finland
Transfer of stem cells from foreign registered donator
+∞
6.3
6
*
E78.0
ICD-10 Finland
Pure hypercholesterolaemia
0.3
6.2
18
486
R18
ICD-10 Finland
Ascites
6.4
6.2
15
24
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
310
450
20.41
238.16
18.5
3.9
459.8
247.4
u/l
28.45
303
422
142
59
34.88
208.59
1.5
1.1
76.7
27.3
u/l
1.86
127
51
130
68
26.59
173.48
1.9
1.6
—
—
—
0
0
257
520
10.33
140.36
7.3
2.5
2.4
1.8
%
9.02
237
474
223
387
10.55
138.80
8.0
2.6
85.9
70.2
e9/l
5.29
187
314
102
59
22.13
128.81
15.6
3.9
2.6
0.8
%
5.30
88
49
175
265
10.24
120.16
19.3
4.4
2.0
0.4
%
12.35
106
74
134
207
8.83
88.42
2.4
1.9
0.8
1.5
g/l
12.77
118
186
216
555
6.62
86.92
3.2
2.4
25.4
22.4
%
1.72
182
474
102
114
11.31
86.68
2.3
1.7
—
—
—
0
0
63
30
24.30
85.51
1.3
1.1
—
—
—
0
0
218
585
6.34
83.12
3.1
2.3
2.2
2.3
g/l
1.51
206
535
224
631
6.13
80.50
3.2
2.4
13.6
12.7
umol/l
0.91
212
576
76
72
12.52
71.83
8.7
6.8
1302.2
225.2
iu/ml
—
9
12
270
1006
5.28
66.96
7.2
2.8
2277.3
10493.3
umol/l
3.06
249
844
56
41
15.48
61.54
17.8
3.3
63.9
55.4
%
0.92
37
29
336
1725
4.87
49.59
24.2
5.6
20.0
26.4
%
20.87
323
1600
55
59
10.50
47.23
9.8
2.9
66.5
59.1
%
2.20
55
59
52
55
10.57
45.06
4.8
1.9
31.0
32.8
pg
1.61
52
55
316
1699
3.97
40.03
18.8
5.4
64.0
58.1
%
11.48
301
1585
286
1482
3.60
37.43
5.5
2.6
381.9
151.1
ug/l
3.02
274
1337
225
1018
3.45
36.43
2.8
2.1
5.4
3.2
mg/l
6.01
203
858
31
24
13.81
32.60
11.1
4.0
—
—
—
0
0
331
1997
3.57
31.58
18.6
6.4
14.2
12.0
umol/l
1.16
323
1899
29
23
13.42
30.03
1.7
1.6
—
—
—
0
0
29
23
13.42
30.03
1.7
1.6
—
—
—
0
0
137
521
3.35
28.28
5.5
5.4
1.1
1.0
mmol/l
2.90
126
473
333
2110
3.30
27.32
30.0
8.6
7.3
4.2
e9/l
7.65
318
1862
155
647
3.14
27.22
5.3
3.3
0.8
0.8
mmol/l
0.44
147
594
103
347
3.56
25.52
2.8
3.1
66.2
66.1
g/l
0.00
94
316
42
70
6.52
24.67
3.7
1.9
—
—
—
0
0
48
94
5.60
23.91
3.6
1.8
—
—
—
0
0
47
92
5.59
23.42
4.1
1.8
—
—
—
0
0
148
657
2.88
22.68
3.1
1.9
32.4
29.5
s
5.67
141
632
35
56
6.70
21.32
1.4
1.3
—
—
—
0
0
25
29
9.07
19.96
5.7
2.1
3753.4
653.1
e6/l
0.42
14
12
21
19
11.55
19.91
2.5
1.6
15.4
13.3
%
—
7
9
299
1967
2.59
19.54
11.5
7.1
1.2
1.2
mmol/l
3.35
237
1666
18
13
14.39
19.45
12.4
5.0
60.7
47.9
%
0.72
18
13
21
20
10.97
19.25
5.9
1.8
—
—
—
0
0
21
20
10.97
19.25
5.9
1.8
—
—
—
0
0
21
21
10.45
18.62
5.9
1.8
—
—
—
0
0
85
307
3.19
18.45
3.7
3.8
1.2
1.2
mmol/l
3.12
73
262
22
24
9.59
18.35
5.7
1.8
—
—
—
0
0
22
24
9.59
18.35
5.7
1.8
—
—
—
0
0
22
24
9.59
18.35
5.7
1.8
—
—
—
0
0
22
24
9.59
18.35
5.7
1.8
—
—
—
0
0
161
827
2.48
17.69
2.0
1.8
1272.8
1173.7
nmol/l
0.58
117
618
29
47
6.53
17.41
4.8
1.8
—
—
—
0
0
29
48
6.39
17.06
4.8
1.8
—
—
—
0
0
30
53
6.00
16.55
1.5
1.2
287.3
288.1
u/ml
0.00
15
27
29
50
6.13
16.39
1.3
1.4
—
—
—
0
0
80
301
3.02
16.08
2.7
1.6
—
—
—
0
0
262
1713
2.29
16.00
9.2
4.9
35.5
35.0
g/l
0.82
249
1591
26
41
6.67
16.00
5.0
1.7
—
—
—
0
0
26
41
6.67
16.00
5.0
1.7
—
—
—
0
0
26
41
6.67
16.00
5.0
1.7
—
—
—
0
0
102
445
2.68
15.51
8.8
2.8
6.9
9.2
umol/l
1.18
95
399
23
33
7.30
15.40
1.2
1.2
49.8
42.4
u/l
0.38
17
23
181
1028
2.28
15.40
2.1
1.6
17.9
20.8
nmol/l
1.85
169
856
137
698
2.39
14.94
3.1
1.9
—
—
—
0
0
15
13
11.91
14.49
8.7
1.3
—
—
—
0
0
251
1687
2.12
13.38
2.7
2.1
85.9
94.9
pmol/l
2.33
171
862
264
1816
2.12
13.14
9.7
6.1
1.2
1.2
mmol/l
1.10
245
1606
16
18
9.18
12.96
1.6
1.7
—
—
—
0
0
18
24
7.77
12.79
1.2
1.6
—
—
—
0
0
31
73
4.49
12.40
2.4
2.6
12.9
15.6
%
1.73
15
35
43
130
3.55
12.25
5.1
3.6
1.2
2.6
ratio
—
6
12
15
17
9.10
12.06
1.3
1.7
2244.4
971.8
u/ml
0.51
15
17
43
133
3.47
11.83
5.2
3.7
118.2
107.6
mg/l
0.04
34
108
43
133
3.47
11.83
5.2
3.7
45.8
30.1
mg/l
0.65
35
109
83
371
2.52
11.80
2.0
2.3
0.2
0.2
g/l
0.25
71
348
248
1709
2.02
11.79
18.4
4.2
—
—
—
0
0
361
2879
2.35
11.38
25.4
7.7
97.6
80.0
u/l
6.34
351
2675
48
165
3.14
11.15
3.3
2.7
3.2
3.7
g/l
1.91
28
125
48
166
3.12
11.04
3.3
2.7
—
—
—
0
0
48
166
3.12
11.04
3.3
2.7
6.7
7.5
g/l
2.09
30
128
13
14
9.54
10.81
1.5
1.4
—
—
—
0
0
45
155
3.12
10.41
3.5
2.7
11.5
9.9
g/l
0.60
36
138
21
41
5.33
10.41
3.3
2.5
—
—
—
0
0
15
21
7.36
10.19
1.6
1.9
18.1
3.7
u/l
—
10
12
84
405
2.32
10.02
4.2
3.5
—
—
—
0
0
38
124
3.26
9.61
1.8
1.2
—
—
—
0
0
9
0
+∞
9.40
1.1
0.0
—
—
—
0
0
134
815
1.92
8.54
2.0
1.7
1.5
1.3
mg/l
0.25
103
640
10
11
9.28
8.11
1.0
1.1
—
—
—
0
0
18
40
4.65
7.71
1.6
1.8
—
—
—
0
0
40
153
2.77
7.69
3.7
2.8
3.3
3.2
g/l
0.38
28
127
88
486
2.01
7.32
2.0
1.8
—
—
—
0
0
18
42
4.42
7.28
1.5
1.9
—
—
—
0
0
22
60
3.81
7.28
1.5
1.7
—
—
—
0
0
10
5
20.41
7.16
1.1
1.0
85.5
113.0
%
—
10
5
192
1363
1.72
7.07
3.3
3.1
3097.0
1535.9
ng/l
2.55
172
1184
87
485
1.99
7.03
2.1
1.9
—
—
—
0
0
23
68
3.51
6.79
1.8
1.6
—
—
—
0
0
14
28
5.13
6.75
4.9
1.8
—
—
—
0
0
14
28
5.13
6.75
2.6
1.3
—
—
—
0
0
11
9
12.49
6.61
1.0
1.2
—
—
—
0
0
11
9
12.49
6.61
2.0
1.4
—
—
—
0
0
140
926
1.75
6.54
11.3
2.4
—
—
—
0
0
11
18
6.24
6.46
1.2
1.2
—
—
—
0
0
12
22
5.58
6.32
2.9
1.2
—
—
—
0
0
12
22
5.58
6.32
2.9
1.2
—
—
—
0
0
6
0
+∞
6.26
6.8
0.0
—
—
—
0
0
160
1111
1.69
6.21
5.6
3.2
34.0
31.9
u/l
0.59
154
1058
11
19
5.91
6.13
12.2
3.5
422.7
207.4
u/l
2.75
11
19
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
35
141
2.61
6.11
3.5
2.4
0.4
0.3
u/ml
0.11
23
72
19
53
3.70
6.10
4.8
1.4
—
—
—
0
0
19
53
3.70
6.10
4.8
1.4
—
—
—
0
0
19
53
3.70
6.10
4.8
1.4
—
—
—
0
0
19
53
3.70
6.10
1.6
1.8
—
—
—
0
0
37
154
2.53
6.05
3.3
3.0
—
—
—
0
0
9
6
15.27
5.92
1.1
3.8
—
—
—
0
0
282
2281
1.65
5.86
7.6
5.0
6.7
6.8
mmol/l
0.59
274
2143
28
104
2.81
5.71
1.5
1.5
2.2
0.1
iu/ml
—
5
28
18
51
3.64
5.66
5.0
1.4
—
—
—
0
0
18
53
3.50
5.36
5.0
1.4
—
—
—
0
0
62
338
1.97
5.30
2.1
1.9
400.0
383.7
nmol/l
0.19
56
305
18
54
3.43
5.22
5.0
1.4
—
—
—
0
0
10
19
5.36
5.06
1.3
1.4
—
—
—
0
0
51
265
2.04
4.98
5.4
3.8
1.0
2.0
mmol/l
1.10
34
204
12
28
4.38
4.85
2.9
1.3
—
—
—
0
0
19
63
3.11
4.73
1.9
1.7
—
—
—
0
0
35
160
2.29
4.70
2.6
1.7
—
—
—
0
0
9
12
7.63
4.37
1.2
1.4
—
—
—
0
0
17
56
3.12
4.28
1.7
1.7
—
—
—
0
0
52
288
1.91
4.25
5.4
3.7
4.9
5.1
kpa
0.72
46
265
36
175
2.15
4.19
6.0
1.9
—
—
—
0
0
204
1613
1.49
4.09
4.7
4.1
35.4
59.2
ng/l
0.61
168
1236
10
24
4.24
3.90
1.3
1.2
—
—
—
0
0
9
15
6.10
3.83
1.3
1.1
—
—
—
0
0
158
1199
1.49
3.82
3.0
2.5
48.7
56.8
u/l
3.24
145
1107
11
29
3.86
3.82
1.5
1.1
—
—
—
0
0
7
8
8.87
3.78
1.7
1.5
—
—
—
0
0
21
86
2.51
3.60
1.1
1.2
—
—
—
0
0
7
10
7.09
3.37
1.1
1.0
—
—
—
0
0
10
28
3.63
3.21
1.7
2.0
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
8
15
5.41
3.20
1.1
1.3
—
—
—
0
0
24
111
2.23
3.19
2.1
1.5
—
—
—
0
0
311
2740
1.45
3.17
6.1
4.1
17.2
13.7
mm/h
2.17
285
2478
20
86
2.39
3.12
4.6
1.3
—
—
—
0
0
95
1284
0.67
3.02
3.9
4.0
17.7
8.6
mg/mmol
0.78
63
800
46
278
1.73
2.88
1.8
1.8
—
—
—
0
0
6
9
6.74
2.87
2.3
1.4
—
—
—
0
0
114
858
1.44
2.76
1.6
1.8
568.4
8190091.3
pmol/l
0.50
86
696
142
1113
1.41
2.74
3.8
3.3
0.5
0.5
e6/l
0.07
119
841
7
199
0.34
2.74
1.4
1.8
—
—
—
0
0
47
291
1.69
2.70
3.7
2.6
40.2
59.9
ml/min/173m2
5.05
25
119
8
20
4.05
2.58
1.8
2.0
—
—
—
0
0
165
1343
1.36
2.50
4.1
3.5
2.3
2.4
mmol/l
2.63
143
1146
9
26
3.51
2.49
1.8
1.8
—
—
—
0
0
9
26
3.51
2.49
1.0
1.0
—
—
—
0
0
8
21
3.86
2.47
1.8
1.9
—
—
—
0
0
214
1817
1.34
2.45
2.6
2.5
—
—
—
0
0
124
978
1.37
2.26
4.4
4.3
0.0
0.0
estimate
0.00
69
304
9
29
3.15
2.23
1.0
1.0
—
—
—
0
0
5
9
5.60
2.22
1.0
1.2
—
—
—
0
0
17
80
2.17
2.21
2.0
1.3
—
—
—
0
0
17
80
2.17
2.21
2.0
1.3
—
—
—
0
0
6
15
4.04
2.04
2.5
1.1
—
—
—
0
0
11
44
2.54
2.02
1.1
1.5
92.9
64.1
%
—
5
34
19
98
1.98
1.98
1.5
1.4
—
—
—
0
0
10
39
2.60
1.93
1.4
1.3
—
—
—
0
0
0
52
0.00
1.89
0.0
1.4
—
—
—
0
0
337
3594
0.74
1.89
5.0
5.4
2.2
2.6
mmol/l
16.65
307
3257
5
12
4.20
1.83
1.2
1.2
—
—
—
0
0
9
35
2.60
1.81
1.1
1.1
—
—
—
0
0
21
117
1.83
1.77
1.1
1.2
—
—
—
0
0
101
801
1.34
1.75
4.4
3.2
2.4
2.5
mmol/l
3.54
88
696
9
36
2.53
1.75
1.1
1.1
—
—
—
0
0
100
1236
0.75
1.71
3.3
4.8
23.3
21.1
%
0.83
48
640
163
1385
1.28
1.70
4.5
4.3
—
—
—
0
0
170
1455
1.27
1.67
4.2
3.4
—
—
—
0
0
34
504
0.65
1.66
10.4
7.7
—
—
—
0
0
66
494
1.39
1.64
6.3
8.0
4.8
5.1
kpa
1.82
66
471
204
1789
1.26
1.62
5.6
5.6
0.0
0.0
estimate
0.00
75
316
203
1789
1.25
1.52
4.2
4.0
0.0
0.0
estimate
0.00
78
318
63
817
0.73
1.49
3.9
4.4
1.0
1.0
kg/l
1.36
12
119
54
398
1.41
1.48
3.5
3.6
1.9
2.1
mmol/l
0.10
40
318
16
88
1.85
1.43
1.2
1.2
618.3
544.3
mg/l
0.14
16
82
54
401
1.39
1.42
3.5
3.6
5.6
5.8
kpa
0.72
54
390
317
3372
0.79
1.41
5.8
6.6
37.3
40.8
mmol/mol
10.10
292
3100
204
1814
1.23
1.37
4.2
4.1
0.0
0.0
estimate
0.50
77
306
5
17
2.96
1.36
2.6
5.9
—
—
—
0
0
333
3517
0.79
1.34
5.3
5.0
6.0
6.1
mmol/l
0.61
290
3166
6
24
2.52
1.31
1.0
1.2
—
65.0
—
0
6
332
3504
0.79
1.30
4.7
4.8
3.9
4.5
mmol/l
20.79
301
3200
5
18
2.80
1.29
1.2
1.2
—
—
—
0
0
5
18
2.80
1.29
1.0
1.3
—
—
—
0
0
11
55
2.03
1.28
1.1
1.1
—
—
—
0
0
27
179
1.54
1.27
3.7
7.2
2.1
1.5
%
1.50
27
167
73
584
1.30
1.20
33.6
25.5
1.7
1.3
inr
1.48
11
77
12
64
1.90
1.19
1.6
1.4
—
—
—
0
0
330
3475
0.81
1.18
4.7
4.7
1.2
1.5
mmol/l
24.77
299
3145
170
1502
1.21
1.18
2.4
2.2
78.4
78.1
nmol/l
0.05
151
1289
0
34
0.00
1.16
0.0
1.2
—
2.0
—
0
13
7
34
2.08
1.03
1.1
1.1
—
—
—
0
0
73
882
0.79
1.02
2.5
3.2
0.9
0.8
ug/l
0.34
49
623
10
53
1.91
1.02
1.1
1.3
0.6
0.5
nmol/l
—
10
47
370
3549
1.25
1.00
41.7
16.6
18.8
25.2
mg/l
5.24
345
2849
35
259
1.38
0.98
1.8
1.4
—
—
—
0
0
23
157
1.49
0.98
1.1
2.0
32.3
39.4
u/l
0.64
18
138
84
992
0.81
0.96
1.8
1.6
1.7
1.3
mmol/l
2.99
72
813
6
27
2.24
0.94
1.0
1.1
—
—
—
0
0
12
71
1.71
0.89
1.2
1.1
—
—
—
0
0
6
29
2.08
0.89
1.0
1.2
—
—
—
0
0
15
96
1.58
0.85
1.5
1.5
—
—
—
0
0
138
1537
0.85
0.83
4.3
5.4
3.4
2.7
ug/l
0.29
129
1367
14
89
1.59
0.82
1.1
1.3
—
—
—
0
0
9
150
0.59
0.80
1.4
1.7
—
—
—
0
0
40
317
1.29
0.75
2.1
3.8
80.6
82.1
ng/l
0.04
33
278
44
354
1.27
0.74
3.0
2.4
35.6
33.2
u/l
0.19
37
293
47
571
0.80
0.71
1.3
1.3
25.9
38.1
iu/ml
0.61
20
189
234
2191
1.14
0.71
4.6
3.3
92.2
54.9
u/l
3.29
222
2011
12
179
0.66
0.67
1.3
1.2
66.0
161.8
iu/ml
—
5
69
11
166
0.65
0.65
1.4
1.9
—
—
—
0
0
59
500
1.21
0.64
6.9
7.9
0.3
1.3
mmol/l
0.72
43
390
5
29
1.73
0.64
1.2
1.1
—
—
—
0
0
49
409
1.22
0.62
7.5
8.9
104.6
120.5
g/l
5.65
49
398
0
21
0.00
0.60
0.0
2.5
—
—
—
0
0
0
21
0.00
0.60
0.0
2.5
—
—
—
0
0
0
21
0.00
0.60
0.0
1.1
—
297.6
—
0
13
378
3871
0.84
0.60
65.4
24.2
114.5
134.1
g/l
56.81
371
3803
22
166
1.34
0.60
2.5
3.2
1.4
1.4
mmol/l
0.11
22
161
378
3870
0.85
0.59
64.9
24.0
3.9
4.4
e12/l
24.86
369
3753
378
3869
0.85
0.58
65.1
24.0
308.9
239.4
e9/l
10.31
371
3767
8
54
1.49
0.57
2.1
4.2
—
—
—
0
0
6
37
1.63
0.55
1.2
1.1
—
—
—
0
0
135
1239
1.13
0.54
2.2
2.1
77.3
203.3
u/l
9.30
124
1161
47
546
0.84
0.48
1.3
1.3
14.6
15.6
u/ml
0.03
18
197
275
2643
1.11
0.46
4.3
3.8
15.2
15.0
pmol/l
0.96
253
2327
317
3073
1.11
0.43
42.5
18.0
34.3
39.2
%
9.27
175
2018
8
56
1.44
0.42
1.4
1.2
19.0
21.9
iu/l
—
8
47
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
8
60
1.34
0.40
1.8
1.8
213.6
234.6
pmol/l
—
8
53
0
18
0.00
0.40
0.0
1.4
—
—
—
0
0
0
19
0.00
0.39
0.0
1.0
—
1.0
—
0
11
48
421
1.16
0.39
1.3
1.4
—
—
—
0
0
40
458
0.86
0.36
3.7
4.2
3.1
42.1
ug/l
1.47
26
386
35
403
0.86
0.34
2.3
2.4
4.6
6.9
ug/l
0.84
27
354
6
44
1.37
0.34
1.3
1.7
—
—
—
0
0
14
109
1.29
0.34
1.3
2.1
—
—
—
0
0
39
341
1.16
0.33
3.5
2.8
4.1
4.4
kpa
0.60
39
329
330
3370
0.92
0.30
4.7
4.3
1.5
1.3
mmol/l
3.84
298
3033
24
203
1.19
0.30
2.8
3.6
23.9
24.2
mmol/l
0.13
24
188
28
321
0.86
0.27
1.4
1.8
1.8
1.6
%
0.35
21
268
85
794
1.09
0.26
4.0
3.9
316.2
261.2
ng/l
0.10
74
667
15
181
0.82
0.25
3.5
3.8
14.8
1423.8
u/ml
1.01
15
158
0
12
0.00
0.21
0.0
1.5
—
—
—
0
0
11
89
1.24
0.21
1.4
1.5
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
7
63
1.11
0.17
1.4
1.1
—
—
—
0
0
5
69
0.72
0.17
2.8
1.8
—
—
—
0
0
8
71
1.13
0.16
1.3
1.4
—
—
—
0
0
13
114
1.14
0.12
1.3
1.2
—
—
—
0
0
13
114
1.14
0.12
1.3
1.2
—
—
—
0
0
34
362
0.93
0.11
1.4
1.4
—
—
—
0
0
68
706
0.96
0.10
3.8
2.8
0.9
1.1
e6/l
0.33
38
414
5
48
1.04
0.09
1.0
1.9
—
—
—
0
0
14
153
0.91
0.07
1.3
1.3
—
—
—
0
0
7
82
0.85
0.07
1.1
1.2
—
—
—
0
0
7
84
0.83
0.07
1.0
1.1
—
11.0
—
0
8
9
86
1.05
0.07
1.7
1.7
43.4
46.4
nmol/l
—
9
79
8
90
0.89
0.07
1.1
1.3
—
2.4
—
0
16
326
3239
1.02
0.06
5.2
4.7
2.3
2.0
mu/l
2.64
303
2883
68
666
1.02
0.04
3.8
3.1
1.1
2.1
e6/l
0.81
35
378
373
3743
0.98
0.03
43.6
19.9
4.1
4.0
mmol/l
7.27
363
3640
375
3761
0.98
0.02
32.3
11.1
25.1
25.1
u/l
0.01
364
3612
337
3358
1.01
0.02
36.3
15.5
71.6
75.0
ml/min/173m2
2.38
306
2770
14
148
0.94
0.02
2.2
3.0
17.0
63.8
u/ml
1.06
14
142
50
509
0.98
0.02
4.2
4.9
27.9
32.3
%
1.95
38
334
373
3738
0.99
0.01
41.1
19.7
139.0
139.6
mmol/l
3.38
365
3635
14
141
0.99
0.00
3.0
3.0
4.0
4.0
mmol/l
0.45
14
125
71
708
1.00
0.00
1.2
1.2
7.2
1.6
u/ml
0.40
12
179
0
8
0.00
0.00
0.0
3.0
—
—
—
0
0
0
8
0.00
0.00
0.0
3.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
7
70
1.00
0.00
1.1
1.2
—
49.0
—
0
6
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
10.7
—
0
5
0
6
0.00
0.00
0.0
3.5
—
96.5
—
0
6
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
7
76
0.92
0.00
1.1
1.2
—
1.1
—
0
6
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
5
58
0.86
0.00
1.0
1.9
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint CHRONMYELOPRO and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CHRONMYELOPRO | 4.416 [3.64, 5.36] | < 0.001 |
| Birth year | 0.996 [0.99, 1.0] | 0.395 |
During the follow-up period (1.1.1998 — 31.12.2019), 638 out of 1093 females with CHRONMYELOPRO died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CHRONMYELOPRO | 4.304 [3.38, 5.49] | < 0.001 |
| Birth year | 0.988 [0.98, 1.0] | 0.008 |
During the follow-up period (1.1.1998 — 31.12.2019), 708 out of 1119 males with CHRONMYELOPRO died.
Mortality risk
Mortality risk for people of age
years, who have CHRONMYELOPRO.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.402% | 0.735% |
| 5 | 2.414% | 4.819% |
| 10 | 6.333% | 12.442% |
| 15 | 12.699% | 21.902% |
| 20 | 20.929% | 35.833% |
Relationships between endpoints
↥Index endpoint: CHRONMYELOPRO – Chronic myeloproliferative disease
GWS hits: 2
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data